Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
ZaiLab_1310-002_StudyTeam
CONTACT
Lead
Zai Lab (Shanghai) Co., Ltd.
With
This is an open-label, multiple-center, phase 1b/2 study of ZL-1310 in selected solid tumors. ZL-1310 will be administered intravenously at 1.6 mg/kg every 21 days. Primary objectives include safety evaluation and confirmed objective response rate by blinded independent central review
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted